Search

Your search keyword '"Arrigo G"' showing total 919 results

Search Constraints

Start Over You searched for: Author "Arrigo G" Remove constraint Author: "Arrigo G"
919 results on '"Arrigo G"'

Search Results

1. The Open Universe Initiative

3. Insight from an Italian Delphi Consensus on EVAR feasibility outside the instruction for use: the SAFE EVAR Study

5. Towards fabrication of ordered gallium nanostructures by laser manipulation of neutral atoms: study of self-assembling phenomena

6. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

9. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants

12. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study

16. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma

17. Crystallization of nano amorphized regions in thin epitaxial layer of Ge2Sb2Te5

19. Fast-Marching Approach for the Simulation of Directional Etching Processes

20. Therapeutic induction of energy metabolism reduces neural tissue damage and increases microglia activation in severe spinal cord injury

24. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update

33. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

34. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

35. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy

36. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

37. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

38. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

39. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

42. National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio:a pooled analysis of 458 population-based studies in Asian and Western countries

44. Erratum: Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study (BMC nephrology (2019) 20 1 (359))

45. Repositioning of the global epicentre of non-optimal cholesterol

46. National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries

47. Laser-driven proton acceleration via excitation of surface plasmon polaritons into TiO2nanotube array targets

48. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Catalog

Books, media, physical & digital resources